Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis

Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis

Hyperamylasemia is a common complication during lamivudine use. We report a case of a pancreatitis following lamivudine therapy. A careful monitoring of amylase levels during treatment with lamivudine is discussed, mainly in the first weeks, considering the cost of this exam and further complication...

Full description

Bibliographic Details
Main Authors:	Felipe Francisco Tuon, Cristina Maria de Fátima Guastini, Maria Ivete Castro Boulos
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Lamivudine pancreatitis amylases hyperamilasemina hepatitis chronic B hepatitis
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702008000400001&lng=en&tlng=en

Similar Items

Treatment of chronic hepatitis B in Oman experience with lamivudine
by: Upadhyay Dip Amal, et al.
Published: (2003-01-01)

Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
by: Aoran Luo, et al.
Published: (2019-07-01)

Lamivudine for chronic hepatitis B: a brief review
by: Emilio Palumbo

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
by: Chan Ho Park, et al.
Published: (2016-03-01)

Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B
by: Astrid Wiens, et al.

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
by: Joo An Hwang, et al.
Published: (2015-06-01)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
by: EunYoung Ze, et al.
Published: (2014-09-01)

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
by: Jeong Han Kim, et al.
Published: (2014-09-01)

Detection of the YMDD Motif Mutations Rate in Chronic Hepatitis B Patients Treated with Lamivudine
by: Soudbakhsh A, et al.
Published: (2011-06-01)

Detection of the YMDD Motif Mutations Rate in Chronic Hepatitis B Patients Treated with Lamivudine
by: R Rafiei Tabatabaei, et al.
Published: (2011-06-01)

Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B
by: Mangano Carmelo, et al.
Published: (2011-01-01)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
by: Hee-Jeong Jeon, et al.
Published: (2017-09-01)

Successful lamivudine therapy for chronic hepatitis B in the family
by: Nožić Darko
Published: (2006-01-01)

Efficacy and safety on tenofovire therapy in patients with hepatitis B viral infections resistent to lamivudin
by: Katanić N., et al.
Published: (2015-01-01)

Experience with lamivudine treatment for severe acute hepatitis B
by: Verhaz Antonija
Published: (2014-01-01)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
by: Jeong Han Kim, et al.
Published: (2013-09-01)

Predictive value of HBcrAg for lamivudine resistance in patients with chronic hepatitis B
by: LIU Cheng
Published: (2013-11-01)

Lamivudine therapy for hepatitis B in renal transplantation
by: F.R.L. Santos, et al.
Published: (2002-02-01)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
by: Hu Peng, et al.
Published: (2011-08-01)

Efficacy of lamivudine and thymosin alpha-1 combination therapy in treatment of HBeAg-positive chronic hepatitis B: a meta-analysis
by: QI Youtao
Published: (2014-07-01)

Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B
by: HUANG Meijin
Published: (2014-07-01)

Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B
by: MA Yanhong
Published: (2013-08-01)

Case report <br> Effective combination of lamivudine with ursodeoxycholic acid in the treatment of acute flare of chronic hepatitis B infection after discontinuation of lamivudine therapy
by: Krisztina Hagymási, et al.
Published: (2005-09-01)

Rhabdomyolysis due to Lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia
by: Janudin Baharin, et al.
Published: (2014-03-01)

The effects of prolonged Lamivudine administration as a sole treatment following the combination therapy of Interferon Alpha and Lamivudine in children for HBeAg (+) chronic hepatitis B
by: Sezin Asik Akman,1 Sabriye Cokceken Okcu,2 Sumer Sutcuoglu.2
Published: (2007-10-01)

Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study
by: Ming-Lun Yeh, et al.
Published: (2016-11-01)

Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B: preliminary comparative study
by: YAN Haiming
Published: (2013-07-01)

Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients
by: Jin Young-Joo, et al.
Published: (2012-10-01)

Evaluation of the therapeutic efficacy of lamivudine combined with plasma exchange for treating acute-on-chronic hepatitis B liver failure
by: HU Qijiang
Published: (2013-02-01)

Clinical study of lamivudine and Biejia Xiaozheng pill combination therapy for chronic hepatitis B
by: LUO Jianjun
Published: (2013-04-01)

Langzeiteffektivität der Therapie mit Lamivudin bei Patienten mit chronischer Hepatitis-B-Virus-Infektion – Prädiktion des Langzeitansprechens und Spektrum der Resistenzentwicklung
by: Brodzinski, Annika
Published: (2015)

Mutation Pattern of Lamivudine Resistance in Relation to Hepatitis B Genotypes
by: Damerow, Hans
Published: (2012)

Tenofovir as Rescue Therapy Following Clinical Failure to Lamivudine in Severe Acute Hepatitis B
by: Jurgen Gerada, et al.
Published: (2013-06-01)

Effect of the sequential therapy of lamivudine and 毩-interferon on cellular immune function as well as serum PD-1 and Tin-3 levels in patients with chronic hepatitis B
by: Yan Jin, et al.
Published: (2016-07-01)

Nonresponse to 18-month Lamivudine Monotherapy in Chronic Hepatitis B Patients with Dual Genotype B and C Infection and Acute Exacerbation
by: Ming-Jen Sheu, et al.
Published: (2006-01-01)

Probing rate of YMDD motif mutant in lamivudine treatment of Iranian patients with chronic hepatitis B virus infection
by: Ghandehari Freshte, et al.
Published: (2011-01-01)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
by: Jung Gil Park, et al.
Published: (2015-09-01)

Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiencyvirus/hepatitis B virus co-infected patients in Brazil
by: Adriana Cristina da Silva, et al.
Published: (2010-09-01)

HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review
by: Yun Zhang, et al.

Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China
by: Wu Bin, et al.
Published: (2012-11-01)